Health Dictionary Find a Doctor

Anemia of prematurity pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Asra Firdous, M.B.B.S.[2]

Overview

Overview

Anemia of prematurity occurs as a result of a combination of increased blood loss or red blood cell destruction, decreased erythropoietin production, increased erythropoietin metabolism, deficient iron stores, and decreased RBC lifespan. Phlebotomy is the major contributing factor of anemia of prematurity. Term infants tolerate anemia well and do not develop any symptoms and resolve with increasing age. Whereas, in preterm infants these factors exaggerate to cause a severe form of anemia more rapidly.

Pathophysiology

Pathophysiology

The pathogenesis of anemia of prematurity is multifactorial. Anemia of prematurity is the result of a combination of decreased erythropoietin production, increased erythropoietin metabolism, deficient iron stores, decreased RBC lifespan, and blood loss during phlebotomy.[1][2][3]

Physiological anemia in newborns

Normally, all the newborns experience a fall in the haemoglobin concentration during the first few weeks of life. Healthy, full-term infants usually develop anemia around 10-12 weeks of life after birth. Hemoglobin concentration never falls below 10 g/dl in healthy infants. Physiological anemia is well tolerated and does not require any therapy.[2][4][5]

Pathological Anemia of Prematurity

In preterm infants, multiple physiological factors exaggerate and combine to result in pathological anemia. Hemoglobin levels drop rapidly to less than 10 g/dl around 4-6 weeks after birth. Infants with 1-1.5 kg of birthweight have hemoglobin levels around 8 g/dl, whereas infants with birthweight less than 1 kg have hemoglobin levels around 7 g/dl or less. The profound decrease in hemoglobin levels in premature infants produce abnormal signs and symptoms and require a blood transfusion. [2][7]

References

References

  1. Stockman JA, Graeber JE, Clark DA, McClellan K, Garcia JF, Kavey RE (1984). “Anemia of prematurity: determinants of the erythropoietin response”. J Pediatr. 105 (5): 786–92. doi:10.1016/s0022-3476(84)80308-x. PMID 6502312.
  2. 2.0 2.1 2.2 Strauss RG (2010). “Anaemia of prematurity: pathophysiology and treatment”. Blood Rev. 24 (6): 221–5. doi:10.1016/j.blre.2010.08.001. PMC 2981681. PMID 20817366.
  3. “Anemia of Prematurity | Annual Review of Medicine”.
  4. “Anemia of Prematurity | Annual Review of Medicine”.
  5. Alan S, Arsan S (2015). “Prevention of the anaemia of prematurity”. Int J Pediatr Adolesc Med. 2 (3–4): 99–106. doi:10.1016/j.ijpam.2015.10.001. PMC 6372412. PMID 30805447.
  6. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS (1996). “Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects”. J Appl Physiol (1985). 80 (1): 140–8. doi:10.1152/jappl.1996.80.1.140. PMID 8847295.
  7. “Anemia of Prematurity | Annual Review of Medicine”.
  8. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, Bartmann P; et al. (1998). “Erythropoietin mRNA expression in human fetal and neonatal tissue”. Blood. 92 (9): 3218–25. PMID 9787158.

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH